...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: https://scr.zacks.co...

Excellent piece, narmac.

Worth repeating on the RVX HUB, don't you think as it is very much applicable there as well?

 

Koo

Share
New Message
Please login to post a reply